Quantcast

Latest Aprepitant Stories

2010-03-01 08:06:46

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation. But a Loyola University Health System study has found the drug aprepitant can dramatically reduce both nausea and vomiting when combined with other anti-nausea drugs. Seventy-three percent of patients receiving aprepitant experienced no vomiting during the study period, compared with 23 percent of patients who received a placebo. (Both...

2009-10-15 14:07:00

Novel HIV Drug to be Studied in Cell Cultures and in Patients PHILADELPHIA, Oct. 15 /PRNewswire-USNewswire/ -- A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection -- a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS. Unlike many current HIV treatments, which are combinations of antiretroviral drugs,...

ea4c660ad7fa4243df8d713a76d3b8c31
2009-04-19 09:00:00

Some 14 years ago, a family of biological compounds found in sponges in the South Pacific was shown to have very promising effects in fighting leukemia.  Further studies have been stifled for years however by the scarcity of the substance.But a group of researchers at the Scripps Research Institute has recently discovered a way to circumvent this problem.Using a few basic amino acids, acetylene gas and a tremendous bit of ingenuity, the research team has developed a technique for...

2008-12-04 07:00:00

WALTHAM, Mass., Dec. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Helsinn Healthcare's Aloxi's marketing message ("Better in acute, better in delayed") is rated the most influential by oncologists in the chemotherapy-induced nausea and vomiting drug market. Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging...

2008-09-16 09:00:53

ProStrakan Group has received the FDA approval for Sancuso, which is reported to be the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately or highly nausea-inducing chemotherapy regimen. According to the company, Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established inhibitor of nausea and vomiting, through a thin layer of adhesive that attaches the...

2008-09-15 09:00:11

BEDMINSTER, N.J., Sept. 15 /PRNewswire-FirstCall/ -- ProStrakan Group plc today announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO(R) (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen. Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly...

2008-06-24 09:03:24

AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments. The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July...

2008-06-24 02:29:21

Investor Relations Contacts: Lippert/Heilshorn & Associates Don Markley, 310-691-7100 dmarkley@lhai.com or Company Contacts: A.P. Pharma, Inc. Gregory Turnbull, President and Chief Executive Officer 650-366-2626 Logo: http://www.appharma.com A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, has completed patient enrollment in its pivotal Phase 3 study in chemotherapy-induced nausea and vomiting (CINV) comparing the efficacy of APF530 (a proprietary,...

2008-01-30 15:00:49

The FDA has approved Merck & Co.'s injectable version of Emend, an intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting. Emend (fosaprepitant dimeglumine) for injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic cancer chemotherapy, including high-dose cisplatin. The FDA approval for...

2008-01-29 15:00:13

Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND(R) (fosaprepitant dimeglumine) for Injection, a new intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (CINV). EMEND for Injection is an intravenous prodrug of the oral formulation of EMEND(R) (aprepitant), which means that when EMEND for Injection is administered, fosaprepitant is rapidly converted in the body to aprepitant. EMEND for Injection is approved...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.